| Code | CSB-RA761623MB2HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to PYX-106, targeting SIGLEC15 (Sialic Acid-Binding Ig-Like Lectin 15), a transmembrane protein that plays crucial roles in osteoclast differentiation and immune regulation. SIGLEC15 functions independently of RANKL in promoting bone resorption and is expressed on tumor-associated macrophages within the tumor microenvironment, where it mediates immunosuppression by inhibiting T cell activation. This dual functionality implicates SIGLEC15 in both skeletal disorders and cancer immune evasion, making it a compelling therapeutic target for osteoporosis, bone metastases, and various malignancies.
PYX-106, the reference antibody developed by Pioneering Medicines (formerly Pyxis Oncology), is an investigational immunotherapy designed to normalize the tumor immune microenvironment by blocking SIGLEC15-mediated immune suppression. This biosimilar antibody provides researchers with a valuable tool for investigating SIGLEC15 biology, studying immune checkpoint mechanisms distinct from PD-1/PD-L1 pathways, exploring osteoclast function, and evaluating combination immunotherapy strategies in preclinical models of cancer and bone disease.
There are currently no reviews for this product.